⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236987 | 0.74 | — | — | |
| SCHEMBL1966530 | 0.71 | — | — | |
| SCHEMBL130843 | 0.71 | — | — | |
| SCHEMBL28363585 | 0.70 | CYP11B1 (0.50) | — | |
| SCHEMBL15884464 | 0.69 | — | — | |
| SCHEMBL9889435 | 0.69 | — | — | |
| SCHEMBL1752553 | 0.69 | — | — | |
| SCHEMBL3224996 | 0.69 | NPC1 (0.33) | — | |
| SCHEMBL1195862 | 0.69 | — | — | |
| SCHEMBL27083126 | 0.69 | LRRK2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207268-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | claimed |
| EP-4313053-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2024-02-07 | — | — | EP | claimed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| CN-116969923-A | Heteroaryl amino compounds, methods of preparation and use thereof | 北京鞍石生物科技有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | claimed |
| US-20050020832-A1 | Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2005-01-27 | — | — | US | claimed |
| EP-1479671-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2004-11-24 | — | — | EP | claimed |
| US-20040167142-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. | 2004-08-26 | — | — | US | claimed |
| JP-2002543190-A | — | — | 2002-12-17 | — | — | JP | claimed |
| CN-1358175-A | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | claimed |
| EP-1175408-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | claimed |
| WO-2000066567-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | claimed |